<DOC>
	<DOCNO>NCT03071055</DOCNO>
	<brief_summary>This 24 week open label study assess efficacy bi-weekly ranibizumab patient retinal fluid due exudative macular degeneration refractory monthly therapy .</brief_summary>
	<brief_title>Efficacy Biweekly Ranibizumab ( 0.5 mg ) Exudative Macular Degeneration Retinal Edema Refractory Anti-VEGF</brief_title>
	<detailed_description>This 24 week , open-label , non-randomized , phase II study evaluate intravitreal ranibizumab dose every 14 day subject exudative macular degeneration persistent intraretinal subretinal fluid despite chronic monthly anti-VEGF therapy ( &gt; 6 month ) . Subjects must minimum 5 intravitreal anti-VEGF injection administer every 4-6 week 6 month precede enrollment . Consented , enrolled subject receive multiple open-label intravitreal injection 0.5 mg ranibizumab administer every 14 day ( Â± 3 day ) . Subjects resolution fluid convert monthly ranibizumab remainder study . If fluid recurs , subject return biweekly treatment . Patients assign receive treatment either ranibizumab vial PFSs approximately 10 patient treated delivery method option , syringe preparation time ( SPT ) measure assistant observing procedure timing automate stopwatch .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Papilledema</mesh_term>
	<mesh_term>Retinal Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age &gt; 50 year Exudative age relate macular degeneration study eye involve fovea Best Corrected Visual Acuity ( ETDRS ) letter score study eye &lt; 85 &gt; 24 ( approximate Snellen equivalent 20/20 20/320 ) Persistent intraretinal subretinal fluid SD OCT despite minimum 5 intravitreal antiVEGF injection administer every 46 week 6 month precede enrollment study eye At least 30 day last intravitreal antiVEGF injection study eye Patient receive systemic antiVEGF proangiogenic therapy Patients chronic high dos corticosteroid therapy ( &gt; 10 mg oral prednisone equivalent great 10 day ) Patients chronic immunosuppressant therapy Patients drug know toxic side effect retina e.g . hydroxychloroquine History intravitreal corticosteroid study eye within 4 month baseline Uncontrolled hypertension ( define systolic &gt; 180 mm Hg and/or diastolic &gt; 100 mm Hg patient sit ) History stroke APTC event previous year Any intraocular surgery study eye within 90 day baseline Presence vitreomacular traction study eye Presence significant epiretinal proliferation study eye Evidence active infection either eye Uncontrolled glaucoma study eye define pressure &gt; 25 mmHg maximal medical therapy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Macular Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>Lucentis</keyword>
</DOC>